3-in-1 Blood Pressure Pill Could Be Treatment Advance
By Dennis Thompson HealthDay Reporter
WEDNESDAY, Sept. 4, 2024 -- An experimental three-in-one blood pressure pill works better than layering on meds one at a time, a new clinical trial shows.
After a month on the combo pill, 81% of patients had their blood pressure under control compared with 55% of patients receiving standard care, researchers report.
“The triple pill still produced clinically meaningful reductions in blood pressure compared to standard care, even when standard care closely followed current guidelines and involved more clinic visits,” said lead investigator Dr. Dike Ojji, head of the Cardiovascular Research Unit at the University of Abuja in Nigeria.
“In low-income countries, fewer than one in four treated people achieve blood pressure control, and in high-income settings it is only between 50% and 70%, so to see rates of over 80% in just one month is impressive,” Ojji added.
The GMRx2 pill, which was developed by the pharmaceutical company George Medicines, contains the blood pressure meds telmisartan, amlodipine and indapamide. It’s taken once daily. The company is part of the George Institute for Global Health.
Researchers compared people taking the combo pill to those receiving standard treatment for high blood pressure, which involves starting off with one drug and then adding on others.
Systolic blood pressure was 31 points lower in the combo pill group after six months of treatment, compared to 26 points lower with standard care, results showed.
The five-point systolic difference is equal to a 10% reduction in stroke, heart attack and heart failure risk between the two groups, researchers said in a George Institute news release.
It’s estimated more than a billion people worldwide have high blood pressure, which accounts for nearly 11 million deaths each year, researchers said in background notes.
George Medicines has submitted the combo drug to the U.S. Food and Drug Administration for approval.
The trial results were presented Saturday at the European Society of Cardiology’s annual meeting in London and published simultaneously in the Journal of the American Medical Association. Positive data from two other trials of the combo pill were also presented at the meeting.
Sources
- George Institute for Global Health, news release, Aug. 31, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Almost 1 in 4 U.S. Adults Under 40 Have High Blood Pressure
FRIDAY, Sept. 6, 2024 -- An epidemic of high blood pressure is occurring in young adults and children in the United States, a pair of new studies show. Nearly a quarter of people...
Cuffs on At-Home Blood Pressure Monitors Don't Fit Some Patients
FRIDAY, Sept. 6, 2024 -- People are encouraged to monitor their blood pressure at home, but many folks will find that household blood-pressure cuffs are literally a bad fit, a new...
Could Your Cellphone Be Harming Your Heart?
WEDNESDAY, Sept. 4, 2024 -- Your cellphone might be harming your heart, a new study warns. People who regularly use a cellphone have a higher risk of heart disease, researchers...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.